The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.

ABSTRACT:

Objective

Cilostazol is indicated for alleviating intermittent claudication (IC) in stable-phase peripheral arterial disease (PAD) patients. Conducting data mining on adverse events (AEs) of cilostazol in the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to explore its potential medication risks and advance more rational and secure clinical medication practices.

Methods

This study utilized the Open Vigil 2.1-MedDRA tool to retrieve and extract AE reporting data related to cilostazol from the FAERS database spanning the first quarter of 2004 to the first quarter of 2024. The primary methodology employed was the application of the reporting odds ratio (ROR) method to detect risk signals associated with AEs of cilostazol.

Results

SUBMITTER: Peng L 

PROVIDER: S-EPMC11616863 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature